Evidence map›Paper›PMID 42141279›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Estimation of split renal function on PET using the SSTR-targeting radioligands [

Maximilian Tiling, Lena M Unterrainer, Sophie C Siegmund, Josef Zahner, Zachary Ells, Franz J Gildehaus, Gabriel T Sheikh, Marcus Unterrainer, Konrad Klimek, Mathias J Zacherl and 4 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maximilian TilingDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany. Maximilian.Tiling@med.uni-muenchen.de.ORCID 0009-0004-6862-2196
Lena M UnterrainerDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Sophie C SiegmundDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Josef ZahnerDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Zachary EllsDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Franz J GildehausDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Gabriel T SheikhDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Marcus UnterrainerDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Konrad KlimekDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Mathias J ZacherlDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Guido BöningDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Astrid DelkerDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
Adrien HolzgreveDepartment of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSSTR-PET is routinely used to select patients with neuroendocrine neoplasms (NEN) for peptide receptor radionuclide therapy (PRRT). As the kidneys are organs at risk, this study evaluated whether renal uptake on pre-therapeutic SSTR-PET/CT reflects split or global renal function and correlates with renal absorbed dose during [

methodsIn this retrospective study, 85 NEN patients treated with [

resultsRenal uptake on SSTR-PET/CT moderately correlated with split renal function assessed by [

conclusionSSTR-PET/CT showed moderate potential to estimate pre-therapeutic split renal function and renal absorbed dose. However, global renal function could not be reliably estimated using PET/CT. Larger studies are warranted to validate PET/CT-based kidney assessment for individualized PRRT planning.

Indexed as

KidneyNeuroendocrine TumorsOctreotideOrganometallic CompoundsPositron Emission Tomography Computed TomographyReceptors, SomatostatinAdultAgedFemaleHumansKidney Function TestsLigandsMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesGa(III)-DOTATOCLigandsOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Somatostatin[177Lu]Lu-DOTA-TATE therapy[99mTc]Tc-MAG3 scintigraphyDosimetryNeuroendocrine neoplasms (NEN)Renal functionSSTR-PET/CT

Identifiers

PMID42141279
PMCPMC13314680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.